Ardelyx to Present at the Jefferies 2022 Healthcare Conference

Ardelyx, Inc. (Nasdaq: ARDX) has announced that CEO Mike Raab will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 8:30 a.m. ET in New York City.

Rhea-AI Summary

Ardelyx, Inc. (Nasdaq: ARDX) has announced that CEO Mike Raab will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 8:30 a.m. ET in New York City. The event aims to showcase Ardelyx's innovative biopharmaceutical developments, including its approved product IBSRELA and the candidate XPHOZAH, which targets serum phosphorus control in CKD patients. A live webcast of the presentation will be available on the company’s investor website, with a replay accessible for 30 days.

Argus Session date unavailable

+4.37% session move Open Argus

Details

News Market Reaction – ARDX

The recorded move for ARDX in the trading session of this news was +4.37%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., June 3, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022, at 8:30 a.m. ET in New York City.  

To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 30 days following the conference.

About Ardelyx, Inc.

Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA^® (tenapanor) is available in the United States. Ardelyx is developing XPHOZAH^® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium secretagogue program, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-jefferies-2022-healthcare-conference-301560772.html

SOURCE Ardelyx

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Ardelyx CEO Mike Raab speak at the Jefferies Healthcare Conference?

Mike Raab will participate in the Jefferies Healthcare Conference on June 10, 2022, at 8:30 a.m. ET.

What company is Mike Raab the CEO of?

Mike Raab is the CEO of Ardelyx, Inc. (Nasdaq: ARDX).

Where is the Jefferies Healthcare Conference being held?

The Jefferies Healthcare Conference is taking place in New York City.

How can I access Ardelyx's presentation at the conference?

You can access the live webcast of Ardelyx's presentation on their Events & Presentations page in the Investor section of their website.

What is Ardelyx developing for CKD patients?

Ardelyx is developing XPHOZAH, a product candidate for controlling serum phosphorus in CKD patients on dialysis.